FIRVANQ
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 19 Mar 2025)
What this means for you
Registered since 08 Jan 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87715534
- Registration number
- 5651067
- Mark type
- Design + words
- Filed
- 11 Dec 2017
- Published for opposition
- 24 Apr 2018
- Registered
- 08 Jan 2019
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: antibiotics; pharmaceutical preparations, namely, vancomycin for the treatment of colitis and gastrointestinal disorders in oral solution form, powder form and diluent form; pharmaceutical preparations, namely, vancomycin for the treatment of clostridium difficile and staphylococcus aureus colitis in oral solution form, powder form and diluent form
Owner
- AZURITY PHARMACEUTICALS, INC., WOBURN, MA, US
- CutisPharma, Inc., Woburn, MA, US
- CutisPharma, Inc., Wilmington, MA, US
- CutisPharma, Inc., Wilmington, MA, US
Prosecution history
- 19 Mar 2025 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 19 Mar 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 19 Mar 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 19 Mar 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 22 Nov 2024 — TEAS SECTION 8 & 15 RECEIVED
- 08 Jan 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 29 Apr 2020 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 23 May 2019 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 23 May 2019 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 26 Mar 2019 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 26 Mar 2019 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 08 Jan 2019 — REGISTERED-PRINCIPAL REGISTER
- 04 Dec 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 03 Dec 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 27 Nov 2018 — STATEMENT OF USE PROCESSING COMPLETE